Abstract:Butyrate, a metabolite produced by gut bacteria, has demonstrated beneficial effects in the colon and has been used to treat inflammatory bowel diseases. However, the mechanism by which butyrate operates remains incompletely understood. Given that oral butyrate can exert either a direct impact on the gut mucosa or an indirect influence through its interaction with the gut microbiome, this study aimed to investigate three key aspects: (1) whether oral intake of butyrate modulates the expression of genes encoding short-chain fatty acid (SCFA) transporters ( Slc16a1 , Slc16a3 , Slc16a4 , Slc5a8 , Abcg2 ) and receptors ( Hcar2 , Ffar2 , Ffar3 , Olfr78 , Olfr558 ) in the colon, (2) the potential involvement of gut microbiota in this modulation, and (3) the impact of oral butyrate on the expression of colonic SCFA transporters and receptors during colonic inflammation. Specific pathogen-free (SPF) and germ-free (GF) mice with or without DSS-induced inflammation were provided with either water or a 0.5% sodium butyrate solution. The findings revealed that butyrate decreased the expression of Slc16a1 , Slc5a8 , and Hcar2 in SPF but not in GF mice, while it increased the expression of Slc16a3 in GF and the efflux pump Abcg2 in both GF and SPF animals. Moreover, the presence of microbiota was associated with the upregulation of Hcar2 , Ffar2, and Ffar3 expression and the downregulation of Slc16a3 . Interestingly, the challenge with DSS did not alter the expression of SCFA transporters, regardless of the presence or absence of microbiota, and the effect of butyrate on the transporter expression in SPF mice remained unaffected by DSS. The expression of SCFA receptors was only partially affected by DSS. Our results indicate that (1) consuming a relatively low concentration of butyrate can influence the expression of colonic SCFA transporters and receptors, with their expression being modulated by the gut microbiota, (2) the effect of butyrate does not appear to result from direct substrate-induced regulation but rather reflects an indirect effect associated with the gut microbiome, and (3) acute colon inflammation does not lead to significant changes in the transcriptional regulation of most SCFA transporters and receptors, with the effect of butyrate in the inflamed colon remaining intact.

Impact of Butyrate on Small and Large Airways: Effects on Cell Viability, Inflammatory Changes and Permeability

Butyrate Attenuates Intestinal Inflammation in Crohn’s Disease by Suppressing Pyroptosis of Intestinal Epithelial Cells Via the Cgsa-Sting-nlrp3 Axis

Butyrate: Connecting the gut-lung axis to the management of pulmonary disorders

Effects of probiotic treatment on patients and animals with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized control trials

Involvement of the Antioxidant Effect and Anti-inflammatory Response in Butyrate-Inhibited Vascular Smooth Muscle Cell Proliferation

Butyrate Properties in Immune-Related Diseases: Friend or Foe?

Effect of butyrate, a bacterial by-product, on the viability and ICAM-1 expression/production of human vascular endothelial cells: Role in infectious pulpal/periapical diseases

Regulation of type 2 innate lymphoid cell-dependent airway hyperreactivity by butyrate

Involvement of GPR43 Receptor in Effect of Lacticaseibacillus rhamnosus on Murine Steroid Resistant Chronic Obstructive Pulmonary Disease: Relevance to Pro-Inflammatory Mediators and Oxidative Stress in Human Macrophages

Butyrate's (a short-chain fatty acid) microbial synthesis, absorption, and preventive roles against colorectal and lung cancer

Repeated exposure to hydrogen peroxide enhances TGF-ß and LPS dependent inflammatory responses in BEAS-2B cells

Butyrate Protects Barrier Integrity and Suppresses Immune Activation in a Caco-2/PBMC Co-Culture Model While HDAC Inhibition Mimics Butyrate in Restoring Cytokine-Induced Barrier Disruption

Butyrate Shapes Immune Cell Fate and Function in Allergic Asthma

The Short-Chain Fatty Acid Butyrate Attenuates Pulmonary Vascular Remodeling and Inflammation in Hypoxia-Induced Pulmonary Hypertension

Dietary Fiber-Derived Microbial Butyrate Suppresses ILC2-Dependent Airway Inflammation in COPD

The effect of oral butyrate on colonic short-chain fatty acid transporters and receptors depends on microbial status

Rectal administration of butyrate ameliorates pulmonary fibrosis in mice through induction of hepatocyte growth factor in the colon via the HDAC-PPARγ pathway

The effect of short-chain fatty acids on M2 macrophages polarization in vitro and in vivo

Butyrate inhibits iILC2-mediated lung inflammation via lung-gut axis in chronic obstructive pulmonary disease (COPD)

Chronic treatment of β-blocker inhibited mucus hypersecretion and MUC5AC expression exposed to cigarette smoking through β-arrestin2–ERK1/2 pathway

Butyrate to combat obesity and obesity‐associated metabolic disorders: Current status and future implications for therapeutic use